Journal of Pregnancy [57] S. Takekoschi, “Eﬀects of hydroxymethylpyrimidine on isoni- azid and ethionamide induced teratosis,” Gunma Journal of Medical Sciences, vol. 14, pp. 233–244, 1965. [58] J. L. Schardein, Chemically Induced Birth Defects, Marcel Dekker, New York, NY, USA, 3rd edition, 2000. [59] J. T. Good, M. D. Iseman, and P. T. Davidson, “Tuberculosis in association with pregnancy,” American Journal of Obstetrics and Gynecology, vol. 140, no. 5, pp. 492–498, 1981. [60] S. Sonya, D. Guerra, M. Rich et al., “Treatment of multidrug- resistant tuberculosis during pregnancy: a report of 7 cases,” Clinical Infectious Diseases, vol. 36, no. 8, pp. 996–1003, 2003. [61] L. K. Pickering, C. J. Baker, S. S. Long, and J. A. McMillan, Red Book: 2006 Report of the Committee on Infectious Diseases, American Academy of Pediatrics, Elk Grove Village, Ill, USA, 27th edition, 2006. [62] Central TB Division, Managing the Revised National Tuber- culosis Control Programme in your area – A training course; Modules 1-4, New Delhi, India, 2001. [63] Management, Control and Prevention of Tuberculosis. Guide- lines for Health Care Providers (2002–2005), Department of Human Services, Victoria, Australia, 2002. [64] M. Khan, T. Pillay, J. M. Moodley, C. A. Connolly, and the Durban Perinatal TB HIV-1 Study Group, “Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa,” AIDS, vol. 15, no. 14, pp. 1857–1863, 2001. [65] “CDC. Managing Drug Interactions in the Treatment of HIV- Related Tuberculosis [online],” http://www.cdc.gov/tb/TB Drugs/default.htm, 2007. [66] Departments of Health, Immunisation Against Infectious Dis- ease, HMSO, London ,UK, 1996. [67] W. J. Burman, “Issues in the management of HIV-related tu- berculosis,” Clinics in Chest Medicine, vol. 26, no. 2, pp. 283– 294, 2005. [68] A. Jindani, A. J. Nunn, and D. A. Enarson, “Two 8-month reg- imens of chemotherapy for treatment of newly diagnosed pul- monary tuberculosis: international multicentre randomised trial,” Lancet, vol. 364, no. 9441, pp. 1244–1251, 2004. [69] A. Okwera, C. Whalen, F. Byekwaso, and The Makerere Uni- versity-Case Western University Research Collaboration, “Randomised trial of thiacetazone and rifampicincontaining regimens for pulmonary tuberculosis in HIV-infected Ugan- dans,” Lancet, vol. 344, no. 8933, pp. 1323–1328, 1994. [70] L. Sarner and A. Fakoya, “Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication,” Sexually Transmitted Infections, vol. 78, no. 1, pp. 58–59, 2002. [71] E. Perucca, R. Grimaldi, G. M. Frigo, A. Sardi, H. Monig, and E. E. Ohnhaus, “Comparative eﬀects of rifabutin and ri- fampicin on hepatic microsomal enzyme activity in normal subjects,” European Journal of Clinical Pharmacology, vol. 34, no. 6, pp. 595–599, 1988. [72] A. Gupta, U. Nayak, M. Ram et al., “Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005,” Clinical Infectious Diseases, vol. 45, no. 2, pp. 241–249, 2007. [73] WHO, Guideline for intensiﬁed tuberculosis case ﬁnding and isoniazide preventive therapy for people living with HIV, WHO, Geneva, Switzerland, 2011. 7